Cobas taqman hiv 1 real time pcr version 2.0 assay

Treatment-naive Vietnamese individuals chronically infected with subtype A/E were recruited from the National Hospital of Tropical Diseases, Vietnam. This study was approved by the Ethics Committee of the Vietnamese Ministry of Health (no. 2342/OD-BYT). Treatment-naive Japanese individuals chronically infected with HIV-1 subtype B were recruited from the National Center for Global Health and Medicine, Japan. This study was approved by the ethics committees of Kumamoto University (RINRI-1340 and GENOME-342) and the National Center for Global Health and Medicine (NCGM-A-000172-01). Three HLA-C*01:02⁺ healthy donors were recruited for this study, which was approved by the Ethical Committee of Kumamoto University, Japan. Informed consent was obtained from all individuals according to the Declaration of Helsinki. PBMCs were separated from whole blood. HLA types of HIV-infected individuals were determined by standard sequence-based genotyping. The pVLs of the individuals at their first visit were measured by using the Cobas TaqMan HIV-1 real-time PCR version 2.0 assay (Roche Diagnostics, NJ).

All treatment-naive Japanese individuals chronically infected with HIV-1 subtype B were recruited between 2007 and 2019 from the National Center for Global Health and Medicine, Japan. This study was approved by the ethics committees of Kumamoto University (RINRI-1340 and GENOME-342) and the National Center for Global Health and Medicine (NCGM-A-000172-01). Informed consent was obtained from all individuals in accordance with the Declaration of Helsinki. Peripheral blood mononuclear cells (PBMCs) were separated from whole blood. The HLA type of HIV-infected individuals was determined by standard sequence-based genotyping. The pVLs of the individuals were measured using the Cobas TaqMan HIV-1 real-time PCR version 2.0 assay (Roche Diagnostics, NJ, USA).